CANCER SCREENING IN IBD David T. Rubin, MD, FACG
|
|
- Hugo Small
- 6 years ago
- Views:
Transcription
1 1C: Advances in Inflammatory Bowel Disease CANCER SCREENING IN IBD David T. Rubin, MD, FACG Risk Factors for Neoplasia in Chronic Colitis An increasing amount of evidence has provided a link between chronically dysregulated inflammatory response and the incidence of cancer. 1 In inflammatory bowel disease, chronically inflamed mucosa has been associated with an increased risk of neoplasia, and the risks for this association have been well-described as increasing duration of disease, greater extent of mucosal involvement, the presence of primary sclerosing cholangitis, and most recently, increased severity of histologic inflammation. Although molecular biomarkers such as inflammation associated DNA damage, including oxidative damage, telomere shortening, and chromosomal instability provide a partial link between inflammation and colorectal neoplasia, 2-4 the mechanism and progression from inflammatory to neoplastic changes in carcinogenesis remain incompletely understood. Nonetheless, there are several studies demonstrating that the severity of inflammation is directly associated with the risk of developing neoplasia. 5-7 These studies suggest that the converse could also be possible; reducing inflammation (with effective treatment) may lower the risk of carcinogenesis. Studies of chemopreventive effects of anti-inflammatory therapies are of interest in this regard, but many are limited by their inability to control for degree of inflammation and therefore their inability to adjust for a major confounding variable. The future approach to cancer prevention will incorporate the compounded risks in an individual patient with appropriate utilization of primary prevention (inflammation control) and secondary prevention (colonoscopic surveillance) in order to prevent dysplasia, cancer and colectomy. Current Recommendations for Surveillance of Colorectal Cancer in Ulcerative Colitis The current approach to cancer prevention in chronic colitis is based on an understanding of the known risk factors and the secondary preventive approach involving screening and surveillance colonoscopy in at risk patients. Current U.S. guidelines as well the British Society of Gastroenterology and other societies and professional organizations share a similar approach. Patients with chronic colitis for 8-10 years should undergo colonoscopy with the intention of identifying dysplasia. Dysplastic changes are associated with a predictive value for both concurrent (synchronous) and subsequent (metachronous) colorectal cancer. 8 Historical precepts in the identification of dysplasia and recommendations for management once it is identified were based on the fact that dysplasia was often not visible and, therefore, must be identified only by microscopic examination of systematic biopsies from the colonic mucosa. The challenges to this approach to cancer prevention include the amount of time required, the lack of adherence to clinical recommendations, and the absence of evidence demonstrating overall benefit. In fact, recent studies demonstrate very low yield of random biopsies, and emerging strategies of surveillance don t require this non-specific approach. 9 Newer technologies have provided information that has modified our approach. High definition colonoscopes provide enhanced visualization of the colonic mucosa and, therefore, are able to identify most lesions. 10,11 In addition, there is a renewed appreciation for different grades and morphologies of dysplasia. There is little debate regarding high grade dysplastic lesions. Pathologists are able to identify these with a good degree of reliability (k=0.54) 12 and such lesions have an unacceptably high risk of synchronous or metachronous cancer and therefore warrant colectomy. Low grade dysplastic lesions may have a more conservative approach, depending on the compounded risk factors in the individual patient and the morphology of such lesions. Current evidence supports a conservative approach to endoscopically discreet raised lesions. Such so called polypoid dysplasia, if removed completely, appears to have a favorable prognosis and may be followed, but with a more intensive surveillance protocol (3-6 month follow-up colonoscopy and, depending on subsequent findings, annually afterwards). This may be due to the fact that the molecular or genetic events that contribute to such lesions are similar to the polypoid lesions in the non-colitis patients, but that line of evidence is incomplete. In contrast, lesions that are identified in flat mucosa, either by random biopsies or by enhanced visualization techniques, appear to have a greater likelihood of progression to higher grade lesions, and warrant a more aggressive approach in follow-up, including discussion of colectomy, referral to a surgeon for consultation, and if colectomy is not pursued, an intensive surveillance plan. Multi-focal dysplasia, recurrent dysplasia in sequential examinations, and flat morphology are higher risk patients, and should be referred for colectomy. Chromoscopy There has been great interest in augmentation of our visualization of dysplasia using chromoendoscopy (also called chromoscopy ), primarily dye-spraying with indigo carmine or methylene blue. 13 There are two general principles of this strategy. First, dye-spray enhancement enables better visual- 1C: Advances in Inflammatory Bowel Disease 97
2 ization of raised lesions. Secondly, dye-spray with or without magnification provides views of the cellular patterns. An understanding of pit patterns and their association with dysplasia is necessary in order to utilize this approach. The range of studies using chromoendoscopy has consistently demonstrated a greater number of dysplastic lesions utilizing this approach compared to white light examinations. 14,15 However, none of these studies have demonstrated a change in outcome of the patients, begging the question of whether the dysplasia seen by chromoscopy is in fact an earlier lesion and providing a greater degree of comfort and ability to follow such patients without immediate colectomy. The enhanced visualization with chromoendoscopy combined with the appreciation of the degree of inflammation as a risk factor for dysplasia was incorporated into the 2010 British Society of Gastroenterology guidelines. They discriminate between low, intermediate and high risk groups based on the patient s compounded risks, including inflammation seen during the examination, and recommend the use of chromoscopy. 16 Although not prospectively evidenced-based (none of our cancer prevention guidelines in IBD are), this practical approach appears reasonable. The key to these guidelines, however, is the ability to perform a careful and clean examination with chromoscopy. In the absence of that, due to an inadequate prep, active inflammation limiting histologic interpretation, or when a patient is non-compliant, longer intervals of follow-up should be considered carefully. Future Strategies and Novel Approaches to Surveillance An ideal surveillance approach would be highly sensitive and specific for early stage neoplasia, adequately sample the entire colorectal mucosa, be easy to implement in practice, and be affordable/cost effective. There are several novel techniques that are being developed and may offer stand-alone alternatives for future surveillance or, more likely, be used in conjunction with selective colonoscopic exams. Such techniques include fecal markers of DNA and methylation, or other techniques that provide fluorescent labeling of dysplastic lesions. 17 Skin Cancer and Screening Extensive research has explored the risk of melanoma and nonmelanoma skin cancer within the IBD patient population The increased risk for non-melanoma skin cancer (NMSC) (e.g., squamous cell carcinoma and basal cell carcinoma) has been well recognized among IBD patients, particularly among those on thiopurine therapy. 19,20 One possible mechanism that explains this finding suggests that thiopurine increases the vulnerability to UVA radiation. 19 Several studies have also shown that biologic medication confer an increased risk for melanoma. 20 In contrast, a meta-analysis by Singh and colleagues demonstrated that melanoma risk exists independent of exposure to biologic therapy. 21 Both patients with CD and UC appear at increased risk for melanoma. 21 All IBD patients should be counseled about their risk for skin cancer and specific concerns associated with their medications. This discussion should focus on primary protection (such as sun avoidance and sun protection via sunscreen and clothing) and secondary protection (such as screening). In particular patients on immunosuppressive agents should undergo yearly screening by a dermatologist as suggested by NIH screening guidelines. 22 Lymphoproliferative Disorders The comorbid occurrence of lymphoproliferative disorders and IBD has been described in the literature, particularly among patients on thiopurines. That is not surprising, as data from non-ibd literature has previously demonstrated a relationship between altered immune status (e.g., HIV/ AIDS and post-transplantation patients on immunosuppressives) and lymphoma risk. 23 The French CESAME study is the largest population-based cohort examination of thiopurine use and lymphoproliferative disorders in IBD patients. This study showed that patients who received thiopurines were five times more likely (Hazard Ratio 5.28 ( , p=0.0007) to develop a lymphoproliferative disorder. 24 The majority of these cases were non-hodgkin lymphomas (NHL), a trend that reflects results found in other studies as well. A meta-analysis of lymphoma rates by Siegel et al. demonstrated risk for NHL while on an immunomodulator at 3.6 per 10,000 patient-years. When an immunomodulator and an anti-tnf agent are combined, the risk increases to 6.1 per patient-years. 25 Although there also has been a risk association seen with EBV and lymphoma in these patients, 24 the ubiquitousness of EBV infections has made screening for EBV in IBD patients prior to therapy or as a stratification approach related to lymphoma impractical. Therefore, at the current time, this is not recommended. The increased risk of hepatosplenic T-cell lymphoma (HSTCL) among patients on dual therapy is real but the incidence remains rare. Overall 41 HSTCL cases among IBD patients were reported to the FDA Adverse Event Reporting System (FDA AERS) between Among these, 23 (56%) had prior exposure to combination therapy consisting of anti- TNF and thiopurine agents. 17 patients with HSTCL received thiopurines alone and 1 patient received an anti-tnf agent alone. A literature review from 2010 of all Crohn s disease patients with HSTCL showed that 22 of the 28 HSTCL cases reported had received combination therapy of infliximab and a thiopurine. 27 Another analysis demonstrated elevated risk for young male patients younger than 35 years of age C: Advances in Inflammatory Bowel Disease
3 These statistics noted that there are no specific screening recommendations regarding lymphoproliferative disorders. Physicians should develop an empirically supported strategy to communicate risks associated with therapy to patients. This may include a visual representation of risk per 10,000 patients. 29 Patients should receive enough adequate information to fully understand both benefits and risks of therapy. Cervical Dysplasia and Cervical Cancer Studies addressing cervical dysplasia and cervical cancer have reported conflicting data. Despite two studies that did not show an increased risk for dysplasia or carcinoma 30,31 there have been several other studies that have suggested an increased risk in either cervical abnormalities or cervical cancer. The study done by the St. Mark s hospital was the first that suggested an increased trend in invasive cervical carcinoma. 32 There have been at least two tertiary center studies conducted that demonstrated an increased risk of cervical dysplasia (but not cancer) in IBD patients. 33,34 Singh et al conducted a population based case-control study that suggested an increased odds ratio for cervical abnormalities among IBD patients. 35 More recently a population-based Danish study showed an increased risk for cervical carcinoma (1.51; 95% CI: ) in CD patients, but not in UC patients. 36 There are no specific cervical cancer screening guidelines for women with IBD. Primary prevention should focus on patient education about risks associated with cervical cancer such as high parity, prolonged oral contraceptive use, number of sexual partners, smoking tobacco, and chlamydia infection. In addition, the role of HPV infections and HPV transmission should be discussed as they pertain to cervical cancer. Secondary prevention in cervical cancer should focus on the regular screening recommendations for women. This said, recent data from a health maintenance study conducted among women with IBD (the PIANO cohort study) reported that only 74% of patients were adherent to cervical screening recommendations. 37 Furthermore, despite no available guidelines for IBD patients specifically, enhanced annual screening has been suggested for IBD patients on immunosuppressive drugs and those who smoke cigarettes. 38,39 In addition, more recent recommendations for prevention in the IBD population (and other immune-compromised patients) include HPV vaccination (in both women and men). anal-intraepithelial neoplasia (AIN) is recommended in high risk individuals. These include patients on immunosuppressive drugs and other factors such as HIV+, men who have sex with men, and women with high grade cervical dysplasia. 40 Anal cancer should be ruled out in IBD patients with exuberant perianal tissue, persistent ulceration or anorectal pain or bleeding. There is often a delayed diagnosis in anal cancer due to misdiagnoses of benign strictures. 40 Therefore, even if a stricture appears benign, physicians should keep anal cancer in their differential diagnosis. The approach to anal cancer screening may involve anal Pap smears or biopsies (in the anesthetized patient). The role of HPV vaccination against this malignancy is not clear, but this recommendation seems prudent. Summary Non-CRC Cancer Risks in IBD and IBD Medication In conclusion, multiple studies have shown increased risks for certain non-crc cancers in IBD patients. Prominent cancers related to IBD treatment include: lymphomas associated with thiopurine, the (rare) association between hepatosplenic T-cell lymphoma in young male patients treated with thiopurines and anti-tnf agents, non-melanoma skin cancer in patients treated with thiopurines and anti-tnf agents, and melanoma in patients on anti-tnf agents only. In addition, IBD patients may have higher rates of abnormal cervical Pap smears and cervical cancer, although these studies have demonstrated conflicting data. Although the discussed studies show an association of increased risk for certain cancers, (lymphoma and skin cancer, in particular,) one should remember that the absolute risks are still very low. We should provide patients with a comprehensive overview of the benefits and risks of IBD treatment and facilitate a conversation that can lead to optimal shared decision making and personalized treatment with our patients in clinic. Clinicians may utilize checklists to assure that all recommended screening is completed. Checklists are useful for organizational purposes and to ensure standard of care. At a minimum, a checklist for cancer screening should address colorectal surveillance, cervical cancer assessment and skin cancer screening (Table 1). Anal Cancer The St. Mark s Hospital study observed a higher than expected frequency of anal cancer among IBD patients. Anal cancer is a rare type of squamous cell carcinoma that is HPV-dependent. Though anal cancer is still rare among IBD patients, there is an increased risk in certain circumstances. Screening for 1C: Advances in Inflammatory Bowel Disease 99
4 Table 1: Recommendations for Screening and Prevention of Cancers Related to IBD Colorectal cancer If UC or CD is present in at least 1/3 of the colon, perform annual or bi-annual surveillance colonoscopies with targeted mucosal sampling; chromoscopy preferred if available, to assess for dysplasia after 8 years. Cervical cancer Annual PAP smears if immunocompromised. HPV vaccination both in women and men (3 doses, ages 9-26). Skin cancer Annual visual exam of skin by dermatologist if immunocompromised. Avoidance of excessive sun exposure, judicious use of sunscreen. REFERENCES 1. Sethi G, Shanmugam MK, Ramachandran L, et al. Multifaceted link between cancer and inflammation. Biosci Rep 2012;32(1): Pekow JR, Dougherty U, Mustafi R, et al. mir-143 and mir- 145 are downregulated in ulcerative colitis: Putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis 2012 Jan;18(1): Watanabe T, Kobunai T, Yamamoto Y, et al. Predicting ulcerative colitis-associated colorectal cancer using reverse-transcription polymerase chain reaction analysis. Clin Colorectal Cancer 2011;10(2): Thorsteinsdottir S, Gudjonsson T, Nielsen OH, et al. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nat Rev Gastroenterol Hepatol 2011;8(7): Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126(2): Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: A cohort study. Gastroenterology 2007;133(4): ; quiz Rubin DT, Huo D, Rothe JA, et al. Increased inflammatory activity is an independent risk factor for dysplasia and colorectal cancer in ulcerative colitis: A case-control analysis with blinded prospective pathology review. Gastroenterology 2006;130(4) (suppl 2):A2. 8. Rubin DT, Rothe JA, Hetzel JT, et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 2007;65: van den Broek FJ, Stokkers PC, Reitsma JB, et al. Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: Low yield and absence of clinical consequences. Am J Gastroenterol Epub 2011 Mar Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) Gut 2010;59: Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc 2004;60: Odze RD, Goldblum J, Noffsinger A, et al. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol 2002 Apr;15(4): Odze RD, Goldblum J, Noffsinger A, et al. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol 2002 Apr;15(4): Kiesslich R, Neurtah MF. Chromoendoscopy in inflammatory bowel disease. Gastroenterol Clin North Am 2012 Jun;41(2): Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105(3): Wu L, Li P, Wu J, et al. The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: Meta-analysis of six randomized controlled trials. Colorectal Dis 2012 Apr;14(4): Biancone L, Michetti P, Travis S, et al. European evidencebased consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis 2008;2: Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation Sep;18(9): Long MD, Kappelman MD, Pipkin CA. Nonmelanoma skin cancer in inflammatory bowel disease: A review. Inflamm Bowel Dis 2011;17: Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141: e Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143: e Singh S, Jiv Singh Nagpal S, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: A systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) doi: /j.cgh Skin Cancer Screening DPQ, National Cancer Institute at the National institutes of Health. pdq/screening/skin/healthprofessional/page2. Last accessed: May 29, Bewtra M. Lymphoma in inflammatory bowel disease and treatment decisions. Am J Gastroenterol 2012 Jul;107(7): Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study. Lancet 2009;7;374(9701): Siegel CA, Marden SM, Persing SM. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn s disease: A meta-analysis. Clin Gasteroenterol Hepatol 2009;7(8): Deepak P, Sifuentes H, Sherid M, et al. T-cell non-hodgkin s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: Results of the REFURBISH study. Am J Gastroenterol 2013;108(1): Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn s disease: Case report and literature review. Clin Lymphoma Myeloma Leuk 2010;10(2): C: Advances in Inflammatory Bowel Disease
5 29. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9(1):36-41.e Siegel CA. Review article: Explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther. 2011;33(1): Hutfless S, Fireman B, Kane S, et al. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2008;28: Lees CW, Critchley J, Chee N, et al. Lack of association between cervical dysplasia and IBD: A large case-control study. Inflamm Bowel Dis 2009;15(11): Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343: Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol 2006;12: Kane S, Khatibi B, Reddy D. Use of immunosuppressants results in higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Gastroenterology 2006;130:A-2 (abstract). 36. Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: A population-based nested case-control study. Gastroenterology 2009;136: Rungø C, Simonsen J, Riis L, et al. Risk of cervical dysplasia and cancer in patients with inflammatory bowel disease. J Crohns Colitis 2013;7:S Sheibani S, Martin CF, Cohen RD, et al. Prospective evaluation of adherence to health maintenance in women with inflammatory bowel disease. Gastroenterology 2013;144:S Mahadevan U. Cervical neoplasia risk in IBD: Truth or hysteria? Inflamm Bowel Dis 2009;15(11): ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists. Number 131, November Cervical cytology screening (Replaces Practice Bulletin Number 109, December 2009). Obstet Gynecol 2012 Nov;120(5): Egan L, D Inca R, Jess T, et al. Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (II). J Crohns Colitis 2013 May 7. pii: S (13) C: Advances in Inflammatory Bowel Disease 101
Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis
Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center
More informationDiagnostic techniques for surveillance of dysplasia
January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Diagnostic techniques for surveillance of dysplasia Gerhard Rogler, Department of Gastroenterology
More informationDysplasia 4/19/2017. How do I practice Chromoendoscopy for Surveillance of Colitis? SCENIC: Polypoid Dysplasia in UC. Background
SCENIC: Polypoid in UC Definition How do I practice for Surveillance of Colitis? Themos Dassopoulos, M.D. Director, BSW Center for IBD Themistocles.Dassopoulos@BSWHealth.org Tel: 469-800-7189 Cell: 314-686-2623
More informationHow to characterize dysplastic lesions in IBD?
How to characterize dysplastic lesions in IBD? Name: Institution: Helmut Neumann, MD, PhD, FASGE University Medical Center Mainz What do we know? Patients with IBD carry an increased risk of developing
More informationChromoendoscopy - Should It Be Standard of Care in IBD?
Chromoendoscopy - Should It Be Standard of Care in IBD? John F. Valentine, MD, FACG Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Utah What is the point of
More informationCASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD
CASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD Disclosure Statement NKC: No relevant conflicts to disclose. DTR: No relevant
More informationChromoendoscopy and Endomicroscopy for detecting colonic dysplasia
Chromoendoscopy and Endomicroscopy for detecting colonic dysplasia Ralf Kiesslich I. Medical Department Johannes Gutenberg University Mainz, Germany Cumulative cancer risk in ulcerative colitis 0.5-1.0%
More informationDiagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases
Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases Parakkal Deepak, M.B.B.S., M.S. Assistant Professor of Medicine Division of Gastroenterology John T. Milliken Department
More informationIBD and Cancer: Myths and Facts
IBD and Cancer: Myths and Facts Thomas A. Ullman, MD Medical Director, Faculty Prac>ce Department of Medicine Icahn School of Medicine at Mount Sinai New York, USA Risk of Colorectal Cancer in UC Eaden
More informationStaying Healthy as an IBD patient
Staying Healthy as an IBD patient Crohn s & Colitis Seattle Education Conference March 28, 2015 Karlee Ausk, MD Swedish Gastroenterology Epidemiology Affects >1.4 million Americans Economic burden $2.8
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationCancer Risk with IBD Therapies How to Discuss with your Patients?
Cancer Risk with IBD Therapies How to Discuss with your Patients? Douglas L Nguyen, MD Assistant Clinical Professor of Medicine University of California, Irvine Medical Center H.H. Chao Comprehensive Digestive
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationChromoendoscopy as an Adjunct to Colonoscopy
Chromoendoscopy as an Adjunct to Colonoscopy Policy Number: 2.01.84 Last Review: 1/2018 Origination: 7/2017 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationCRC and Dysplasia in IBD: Objectives of Talk. Colorectal Cancer and Dysplasia in IBD: A Case-Based Approach. Page 1
Colorectal Cancer and in IBD: A Case-Based Approach Fernando Velayos MD MPH Associate Director of Translational Research University of California, San Francisco Center for Crohn s s and Colitis CRC and
More informationMalignancy Risk in Pediatric IBD: What to tell parents and patients?
Malignancy Risk in Pediatric IBD: What to tell parents and patients? Corey A. Siegel, MD, MS Geisel School of Medicine at Dartmouth Dartmouth-Hitchcock Medical Center Digestive Disease Week 2017 Chicago,
More informationBENEFIT APPLICATION BLUE CARD/NATIONAL ACCOUNT ISSUES
Medical Policy BCBSA Ref. Policy: 2.01.84 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 2.01.87 Confocal Laser Endomicroscopy 6.01.32 Virtual Colonoscopy/Computed
More informationQuality in Endoscopy: Can We Do Better?
Quality in Endoscopy: Can We Do Better? Erik Rahimi, MD Assistant Professor Division of Gastroenterology, Hepatology, and Nutrition UT Health Science Center at Houston McGovern Medical School Ertan Digestive
More informationBiologics: Too Risky
Biologics: Too Risky Sharmeel K. Wasan, MD, FACG Assistant Professor of Medicine Boston University School of Medicine Why Anti-TNF Therapy? CD patients have long-term risk of intestinal resection (80%)
More informationAdvances in Endoscopic Imaging
Advances in Endoscopic Imaging SGNA meeting February 20, 2010 Amar R. Deshpande, MD Asst Professor of Medicine Division of Gastroenterology University of Miami Miller School of Medicine Objectives To recognize
More informationIntestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines
INVITED REVIEW Annals of Gastroenterology (2012) 25, 1-8 Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines Vicent Hernández a, Juan Clofent b Complexo Hospitalario
More informationWhen and How to use Chromoendoscopy in IBD
When and How to use Chromoendoscopy in IBD Samir A. Shah, MD, FACG, FASGE, AGAF Clinical Professor of Medicine, Brown University Chief of Gastroenterology, The Miriam Hospital Gastroenterology Associates,
More informationDiagnosis and Management of Flat and Polypoid Dysplasia in Inflammatory Bowel Disease
Diagnosis and Management of Flat and Polypoid Dysplasia in Inflammatory Bowel Disease Francis A. Farraye, MD, MSc Clinical Director, Section of Gastroenterology, Boston Medical Center Professor of Medicine,
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationChromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis
Chromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis Bret A. Lashner, M.D. Professor of Medicine Director,
More informationEndoscopy in IBD. F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M.
F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M. F.Hartmann@em.uni-frankfurt.de Indications for endoscopy Diagnosis Management Surveillance Diagnosis Single most valuable tool: ileocolonoscopy
More informationPatients with longstanding ulcerative colitis (UC) or
ORIGINAL ARTICLE Misclassification of Dysplasia in Patients with Inflammatory Bowel Disease: Consequences for Progression Rates to Advanced Neoplasia Fiona D.M. van Schaik, MD,* Fiebo J.W. ten Kate, MD,
More informationInflammatory bowel disease (IBD), which includes ulcerative
Chromoendoscopy and Dysplasia Surveillance in Inflammatory Bowel Disease: Past, Present, and Future Steven Naymagon, MD, and Thomas A. Ullman, MD Dr Naymagon is an assistant professor of medicine and Dr
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationNew Approaches for Early Detection of Ulcerative Colitis (UC) Associated Cancer and Surgical Treatment of UC Patients
New Approaches for Early Detection of Ulcerative Colitis (UC) Associated Cancer and Surgical Treatment of UC Patients Toshiaki Watanabe, M.D., Ph.D. Department of Surgery, Teikyo University School of Medicine,
More informationAs clinicians we would all agree that the goal for our
CURRENT CONTROVERSIES: PRO, CON, AND BALANCE Controversies in Mucosal Healing in Ulcerative Colitis Sunanda Kane, MD,* Frances Lu, MD, Asher Kornbluth, MD, Dahlia Awais, MD, and Peter D.R. Higgins, MD,
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationThe variable risk of colorectal cancer in patients with inflammatory bowel disease.
The variable risk of colorectal cancer in patients with inflammatory bowel disease. Lindgren, Stefan Published in: European Journal of Internal Medicine DOI: 10.1016/j.ejim.2004.12.001 Published: 2005-01-01
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationRandom biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis
Journal of Crohn's and Colitis (2013) 7, 974 981 Available online at www.sciencedirect.com ScienceDirect Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationEndoscopic Corner CASE 1. Kimtrakool S Aniwan S Linlawan S Muangpaisarn P Sallapant S Rerknimitr R
170 Endoscopic Corner Kimtrakool S Aniwan S Linlawan S Muangpaisarn P Sallapant S Rerknimitr R CASE 1 A 54-year-old woman underwent a colorectal cancer screening. Her fecal immunochemical test was positive.
More informationChemoprevention of Colorectal Neoplasia in Ulcerative Colitis: The Effect of 6-Mercaptopurine
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1015 1021 Chemoprevention of Colorectal Neoplasia in Ulcerative Colitis: The Effect of 6-Mercaptopurine SIERRA MATULA,* VICTORIA CROOG,* STEVEN ITZKOWITZ,*
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationScreening & Surveillance Guidelines
Chapter 2 Screening & Surveillance Guidelines I. Eligibility Coloradans ages 50 and older (average risk) or under 50 at elevated risk for colon cancer (personal or family history) that meet the following
More informationIBD high risk groups
IBD high risk groups Ulcerative colitis Value (95% CI) CRC prevalence (%) 3.7 (3.2-4.2) Overall annual CRC incidence (%) 0.3 (0.2-0.4) Annual CRC incidence in first decade of UC (%) 0.2 (0.1-0.2) Annual
More informationDescription. Section: Medicine Effective Date: July 15, Subsection: Original Policy Date: September 13, 2012 Subject: Page: 1 of 17
Page: 1 of 17 Last Review Status/Date: June 2016 Description Chromoendoscopy refers to the application of dyes or stains during endoscopy to enhance tissue differentiation or characterization. When used
More informationLaboratory Testing: Medication Dependent. The Newly Diagnosed Patient. Why Talk about This? Lack of Primary Care
Why Talk about This? Lack of Primary Care Health Care Maintenance in the IBD Patient Sunanda Kane, MD MSPH FACG FACP AGAF Mayo Clinic Rochester Many patients with IBD are young and do not have co-morbid
More informationMEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY
MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationRole of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer
ORIGINAL ARTICLE pissn 1598-9100 eissn 2288-1956 http://dx.doi.org/10.5217/ir.2016.14.3.264 Intest Res 2016;14(3):264-269 Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients
More informationTreatment of Pediatric IBD: What is Different?
Treatment of Pediatric IBD: What is Different? January 13, 2017 Michael Kappelman MD, MPH University of North Carolina at Chapel Hill Overview Is Pediatric IBD the same disease? Treatment considerations
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationInflammatory Bowel Disease: Clinical updates. Dr Jeff Chao Princess Alexandra Hospital
Inflammatory Bowel Disease: Clinical updates Dr Jeff Chao Princess Alexandra Hospital Inflammatory bowel disease 2017 Clinical updates and future directions Pathogenesis Treatment targets Therapeutic agents
More informationReview article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease
Aliment Pharmacol Ther 23; 18 (Suppl. 2): 1 5. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease P. MUNKHOLM Department of Medical Gastroenterology, Hvidovre
More informationOsteopathic Primary Care of Patients With Inflammatory Bowel Disease: A Review
Osteopathic Primary Care of Patients With Inflammatory Bowel Disease: A Review Jack D. Bragg, DO Financial Disclosures: None reported. Support: None reported. Address correspondence to Jack D. Bragg, DO,
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationIncidence, Management, and Course of Cancer in Patients with Inflammatory Bowel Disease
Journal of Crohn's and Colitis, 2015, 326 333 doi:10.1093/ecco-jcc/jjv032 Advanced access publication February 16, 2015 Original Article Original Article Incidence, Management, and Course of Cancer in
More informationTitle: Serrated polyposis syndrome associated with long-standing inflammatory bowel disease
Title: Serrated polyposis syndrome associated with long-standing inflammatory bowel disease Authors: Jesús Castro, Miriam Cuatrecasas, Francesc Balaguer, Elena Ricart, María Pellisé DOI: 10.17235/reed.2017.5068/2017
More informationLatest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population
Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population David T. Rubin, M.D. Assistant Professor of Medicine Inflammatory Bowel Disease Center MacLean Center for Clinical Medical Ethics
More information21/07/2017. Lymphoproliferations in immunodeficiency. IBD and EBV associated LPD in GIT Han van Krieken. Inflammatory bowel disease and cancer
IBD and EBV associated LPD in GIT Han van Krieken Lymphoproliferations in immunodeficiency Primary immunodeficiencies Large variation in conditions and lesions Acquired immunodeficiencies HIV: changes
More informationHealth Maintenance For Your IBD Patient. Quality in HealthCare
Health Maintenance For Your IBD Patient Francis A. Farraye, MD, MSc Clinical Director Section of Gastroenterology Boston Medical Center Professor of Medicine i Boston University School of Medicine Quality
More informationPresence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation
ORIGINAL ARTICLE Annals of Gastroenterology (2019) 32, 1-6 Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation Dimitrios S. Politis a, Konstantinos
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationObjec-ve. Case Presenta-ons and Ques-ons to Panel. Dysplasia case 11/13/11
Case Presenta-ons and Ques-ons to Panel UCSF IBD Symposium November 12, 2011 Moderator Fernando Velayos MD Panelists Brian Feagan, MD James Lewis, MD MSCE Robert Cima, MD Hueylan Chern, MD Sunanda Kane,
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationPrevention of Complications from IBD Therapies
Prevention of Complications from IBD Therapies July 23, 2011 Millie D. Long MD, MPH Inflammatory Bowel Diseases Center University of North Carolina-Chapel Hill Outline: Complications of IBD Therapies Osteoporosis
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationremoval of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2
Supplementary Table 1. Study Characteristics Author, yr Design Winawer et al., 6 1993 National Polyp Study Jorgensen et al., 9 1995 Funen Adenoma Follow-up Study USA Multi-center, RCT for timing of surveillance
More informationMasato Kusunoki Editor. Colitis-Associated Cancer
Masato Kusunoki Editor Colitis-Associated Cancer 123 Colitis-Associated Cancer ThiS is a FM Blank Page Masato Kusunoki Editor Colitis-Associated Cancer Editor Masato Kusunoki Mie University Graduate School
More informationYearly pelvic exam, or not?
Yearly pelvic exam, or not? Are the new cancer screening guidelines putting patients at risk? Dianna Wachtel, DHSc, PA-C, CCPA CAPA 2018 Learning Objectives Distinguish between current PAP test guidelines
More informationDifferentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics
38 Original Article Differentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics Anuchapreeda S Leelakusolvong S Charatcharoenwitthaya
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationASGE and AGA Issue Consensus Statement on Surveillance and Management of Dysplasia in Patients With Inflammatory Bowel Disease
ASGE and AGA Issue Consensus Statement on Surveillance and Management of Dysplasia in Patients With Inflammatory Bowel Disease DOWNERS GROVE, Ill., (March 5, 2015) The American Society for Gastrointestinal
More informationColorectal Cancer in Inflammatory Bowel Disease
Gut and Liver, Vol. 2, No. 2, September 2008, pp. 61-73 review Colorectal Cancer in Inflammatory Bowel Disease Jonathan Potack and Steven H. Itzkowitz Division of Gastroenterology, Department of Medicine,
More informationRandomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis
Alimentary Pharmacology and Therapeutics Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis G. R. Lichtenstein*,
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/12 REVISED DATE: 11/21/13, 10/16/14 SUBJECT: HIGH RESOLUTION ANOSCOPY
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: 2.01.87 Confocal Laser Endomicroscopy 6.01.32 Virtual Colonoscopy/CT Colonography Chromoendoscopy as an Adjunct to Colonoscopy
More informationPractical Risk Management Tools for Patients with IBD. Garth Swanson MD Rush University Medical Center
Practical Risk Management Tools for Patients with IBD Garth Swanson MD Rush University Medical Center IBD Therapy Severity Tysabri Surgery Infliximab, i Adalimumab, Certilizumab Corticosteroids, Immunomodulators
More informationCommunicating with the IBD Patient: How to convey risks and benefits
Communicating with the IBD Patient: How to convey risks and benefits October 30, 2011 ACG Postgraduate Course National Harbor, Maryland Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical
More informationIMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS ON SAFETY AND RISK MINIMISATION FOR INFLIXIMAB
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationAdvances in Ulcerative Colitis - Volume 3 CME
1 de 12 22/01/2008 04:46 p.m. More: Advances in Ulcerative Colitis Advances in Ulcerative Colitis - Volume 3 CME Complete author affiliations and disclosures are at the end of this activity. Release Date:
More informationHLA TYPING AND EXPRESSION: POTENTIAL MARKER FOR IDENTIFYING EARLY DYSPLASIA AND STRATIFYING THE RISK FOR IBD-CANCER
HLA TYPING AND EXPRESSION: POTENTIAL MARKER FOR IDENTIFYING EARLY DYSPLASIA AND STRATIFYING THE RISK FOR IBD-CANCER Megan Garrity, S. Breanndan Moore, M.D., William Sandborn, M.D., Vernon Pankratz, Ph.D.,
More informationOptimizing Immunomodulators and
Optimizing Immunomodulators and Biologics i in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota,
More informationColon Screening in 2014 Offering Patients a Choice. Clark A Harrison MD The Nevada Colon Cancer Partnership
Colon Screening in 2014 Offering Patients a Choice Clark A Harrison MD The Nevada Colon Cancer Partnership Objectives 1. Understand the incidence and mortality rates for CRC in the US. 2. Understand risk
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationCorporate Medical Policy
Corporate Medical Policy Chromoendoscopy as an Adjunct to Colonoscopy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: chromoendoscopy_as_an_adjunct_to_colonoscopy 7/2012 11/2017
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Patients with Endoscopically Visible Polypoid Adenomatous Lesions Within the Extent of Ulcerative Colitis Have an Increased Risk of Colorectal Cancer Despite Endoscopic Resection.
More informationCrohn s disease and ulcerative colitis are lifelong inflammatory
The new england journal of medicine Review Article Dan L. Longo, M.D., Editor Cancers Complicating Inflammatory Bowel Disease Laurent Beaugerie, M.D., Ph.D., and Steven H. Itzkowitz, M.D. Crohn s disease
More informationOUNCE OF PREVENTION WORTH A POUND OF CURE
Healthcare maintenance in the patient with Inflammatory Bowel Disease. OUNCE OF PREVENTION WORTH A POUND OF CURE Your gastroenterologist is NOT your primary care physician Your gastroenterologist is NOT
More informationIBD-Related Lymphoma
IBD-Related Lymphoma Larry Burgart MD Staff Pathologist, Allina Health and Minnesota Gastroenterology Clinical Professor of Pathology, University of Minnesota College of Medicine IBD-Related Lymphoma
More informationIBD What s in it for you?
Addenbrooke s NHS Trust IBD What s in it for you? Dr Miles Parkes Consultant Gastroenterologist Cambridge What is IBD? - inflammatory bowel disease Ulcerative colitis + Crohn s disease = main forms Incidence
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationNovel Optical Research at UPMC
Novel Optical Research at UPMC Randall Brand, MD Professor of Medicine Division of Gastroenterology, Hepatology, & Nutrition University of Pittsburgh Medical Center Background Patients with UC and CD of
More informationSWL Drug Pathway Ulcerative Colitis Version 3 (Oct 2018) (based on NICE ulcerative colitis commissioning algorithm - with local adaptation)
Adult with active ulcerative colitis Does the adult have moderately to severely active ulcerative colitis managed in outpatients with no need for hospitalisation/surgery? Moderately to severely active
More information